<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="interaction" /><meta name="keywords" content="" /><title>Beclometasone: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="bnf_int495-beclometasone.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="bnf_int495-beclometasone.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=bnf_int495-beclometasone.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 07 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP8848-interactions.htm">Appendix 1 Interactions</a> &gt; <a href="PHP8852-list-of-drug-interactions.htm">List of drug interactions</a> &gt; <a href="bnf_int484-corticosteroids.htm">Corticosteroids</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="bnf_int968-mometasone.htm" title="Previous: Mometasone">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="bnf_int487-betamethasone.htm" title="Next: Betamethasone">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1>Beclometasone</h1><?highlighter on?><div id="pC" class="jN"><p><strong>Beclometasone</strong> has no specific interaction information.</p><p><strong>Beclometasone</strong> belongs to <strong>Corticosteroids</strong> and will have the following interaction information:</p><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to corticosteroids used for topical action (including inhalation) unless specified</p></div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int2-ace-inhibitors.htm">ACE Inhibitors</a></td><td><p><span></span> <span>corticosteroids</span> <span>antagonise hypotensive effect of</span> <span>ACE inhibitors</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int551-acetazolamide.htm">Acetazolamide</a></td><td><p><span>increased risk of hypokalaemia when </span> <span>corticosteroids</span> <span>given with</span> <span>acetazolamide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int15-adrenergic-neurone-blockers.htm">Adrenergic Neurone Blockers</a></td><td><p><span></span> <span>corticosteroids</span> <span>antagonise hypotensive effect of</span> <span>adrenergic neurone blockers</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int21-aldesleukin.htm">Aldesleukin</a></td><td class="cAI"><p><span>avoidance of </span> <span>corticosteroids</span> <span>advised by manufacturer of</span> <span>aldesleukin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int26-alpha-blockers.htm">Alpha-blockers</a></td><td><p><span></span> <span>corticosteroids</span> <span>antagonise hypotensive effect of</span> <span>alpha-blockers</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int290-amphotericin.htm">Amphotericin</a></td><td class="cAI"><p><span>increased risk of hypokalaemia when </span> <span>corticosteroids</span> <span>given with</span> <span>amphotericin</span> <span>—avoid concomitant use unless <span>corticosteroids</span> needed to control reactions</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Close monitoring required with concomitant administration of nephrotoxic drugs or cytotoxics</p></div></td></tr><tr><td><a href="bnf_int107-angiotensin-ii-receptor-antagonists.htm">Angiotensin-II Receptor Antagonists</a></td><td><p><span></span> <span>corticosteroids</span> <span>antagonise hypotensive effect of</span> <span>angiotensin-II receptor antagonists</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int264-antidiabetics.htm">Antidiabetics</a></td><td><p><span></span> <span>corticosteroids</span> <span>antagonise hypoglycaemic effect of</span> <span>antidiabetics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int361-aspirin.htm">Aspirin</a></td><td><p><span>increased risk of gastro-intestinal bleeding and ulceration when </span> <span>corticosteroids</span> <span>given with</span> <span>aspirin</span> <span>, also <span>corticosteroids</span> reduce plasma concentration of salicylate</span>  </p></td><td></td></tr><tr><td><a href="bnf_int440-beta-blockers.htm">Beta-blockers</a></td><td><p><span></span> <span>corticosteroids</span> <span>antagonise hypotensive effect of</span> <span>beta-blockers</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Since systemic absorption may follow topical application of beta-blockers to the eye the possibility of interactions, in particular, with drugs such as verapamil should be borne in mind</p></div></td></tr><tr><td><a href="bnf_int465-calcium-salts.htm">Calcium Salts</a></td><td><p><span></span> <span>corticosteroids</span> <span>reduce absorption of</span> <span>calcium salts</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> see also Antacids</p></div></td></tr><tr><td><a href="bnf_int466-calcium-channel-blockers.htm">Calcium-channel Blockers</a></td><td><p><span></span> <span>corticosteroids</span> <span>antagonise hypotensive effect of</span> <span>calcium-channel blockers</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Dihydropyridine calcium-channel blockers include amlodipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, and nimodipine</p></div></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td class="cAI"><p><span>metabolism of </span> <span>corticosteroids</span> <span>accelerated by</span> <span>carbamazepine</span> <span>(reduced effect)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int478-cardiac-glycosides.htm">Cardiac Glycosides</a></td><td><p><span>increased risk of hypokalaemia when </span> <span>corticosteroids</span> <span>given with</span> <span>cardiac glycosides</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int482-clonidine.htm">Clonidine</a></td><td><p><span></span> <span>corticosteroids</span> <span>antagonise hypotensive effect of</span> <span>clonidine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td class="cAI"><p><span></span> <span>corticosteroids</span> <span>may enhance or reduce anticoagulant effect of</span> <span>coumarins</span> <span>(high-dose <span>corticosteroids</span> enhance anticoagulant effect)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int522-diazoxide.htm">Diazoxide</a></td><td><p><span></span> <span>corticosteroids</span> <span>antagonise hypotensive effect of</span> <span>diazoxide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int524-diuretics.htm">Diuretics</a></td><td><p><span></span> <span>corticosteroids</span> <span>antagonise diuretic effect of</span> <span>diuretics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int539-diuretics-loop.htm">Diuretics, Loop</a></td><td><p><span>increased risk of hypokalaemia when </span> <span>corticosteroids</span> <span>given with</span> <span>loop diuretics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int525-diuretics-thiazide-and-related.htm">Diuretics, Thiazide and related</a></td><td><p><span>increased risk of hypokalaemia when </span> <span>corticosteroids</span> <span>given with</span> <span>thiazides and related diuretics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int169-erythromycin.htm">Erythromycin</a></td><td><p><span>metabolism of </span> <span>corticosteroids</span> <span>possibly inhibited by</span> <span>erythromycin</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not apply to small amounts of erythromycin used topically</p></div></td></tr><tr><td><a href="bnf_int1180-histamine.htm">Histamine</a></td><td><p><span>avoidance of </span> <span>corticosteroids</span> <span>advised by manufacturer of</span> <span>histamine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int763-hydralazine.htm">Hydralazine</a></td><td><p><span></span> <span>corticosteroids</span> <span>antagonise hypotensive effect of</span> <span>hydralazine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int165-isoniazid.htm">Isoniazid</a></td><td><p><span></span> <span>corticosteroids</span> <span>possibly reduce plasma concentration of</span> <span>isoniazid</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int302-itraconazole.htm">Itraconazole</a></td><td><p><span>metabolism of </span> <span>corticosteroids</span> <span>possibly inhibited by</span> <span>itraconazole</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int298-ketoconazole.htm">Ketoconazole</a></td><td><p><span>metabolism of </span> <span>corticosteroids</span> <span>possibly inhibited by</span> <span>ketoconazole</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int611-methyldopa.htm">Methyldopa</a></td><td><p><span></span> <span>corticosteroids</span> <span>antagonise hypotensive effect of</span> <span>methyldopa</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1173-mifamurtide.htm">Mifamurtide</a></td><td><p><span>avoidance of </span> <span>corticosteroids</span> <span>advised by manufacturer of</span> <span>mifamurtide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int614-mifepristone.htm">Mifepristone</a></td><td><p><span>effect of </span> <span>corticosteroids</span> <span>(including inhaledcorticosteroids) may be reduced for 3–4 days after</span> <span>mifepristone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int764-minoxidil.htm">Minoxidil</a></td><td><p><span></span> <span>corticosteroids</span> <span>antagonise hypotensive effect of</span> <span>minoxidil</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int615-moxonidine.htm">Moxonidine</a></td><td><p><span></span> <span>corticosteroids</span> <span>antagonise hypotensive effect of</span> <span>moxonidine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int60-nsaids.htm">NSAIDs</a></td><td><p><span>increased risk of gastro-intestinal bleeding and ulceration when </span> <span>corticosteroids</span> <span>given with</span> <span>NSAIDs</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> See also Aspirin. Interactions do not generally apply to topical NSAIDs
</p></div></td></tr><tr><td><a href="bnf_int631-nitrates.htm">Nitrates</a></td><td><p><span></span> <span>corticosteroids</span> <span>antagonise hypotensive effect of</span> <span>nitrates</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int636-oestrogens.htm">Oestrogens</a></td><td><p><span>plasma concentration of </span> <span>corticosteroids</span> <span>increased by oral contraceptives containing</span> <span>oestrogens</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a></p></div></td></tr><tr><td><a href="bnf_int625-pancuronium.htm">Pancuronium</a></td><td><p><span></span> <span>corticosteroids</span> <span>possibly antagonise effects of</span> <span>pancuronium</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int223-phenindione.htm">Phenindione</a></td><td><p><span></span> <span>corticosteroids</span> <span>may enhance or reduce anticoagulant effect of</span> <span>phenindione</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control  </p></div></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td class="cAI"><p><span>metabolism of </span> <span>corticosteroids</span> <span>accelerated by</span> <span>phenobarbital</span> <span>(reduced effect)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td class="cAI"><p><span>metabolism of </span> <span>corticosteroids</span> <span>accelerated by</span> <span>phenytoin</span> <span>(reduced effect)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int199-rifamycins.htm">Rifamycins</a></td><td class="cAI"><p><span>metabolism of </span> <span>corticosteroids</span> <span>accelerated by</span> <span>rifamycins</span> <span>(reduced effect)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not apply to rifaximin</p></div></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td><p><span>plasma concentration of </span> <span>corticosteroids</span> <span>possibly increased by</span> <span>ritonavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1034-sodium-benzoate.htm">Sodium Benzoate</a></td><td><p><span></span> <span>corticosteroids</span> <span>possibly reduce effects of</span> <span>sodium benzoate</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int765-sodium-nitroprusside.htm">Sodium Nitroprusside</a></td><td><p><span></span> <span>corticosteroids</span> <span>antagonise hypotensive effect of</span> <span>sodium nitroprusside</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1033-sodium-phenylbutyrate.htm">Sodium Phenylbutyrate</a></td><td><p><span></span> <span>corticosteroids</span> <span>possibly reduce effects of</span> <span>sodium phenylbutyrate</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int848-somatropin.htm">Somatropin</a></td><td><p><span></span> <span>corticosteroids</span> <span>may inhibit growth-promoting effect of</span> <span>somatropin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int720-sympathomimetics-beta-2.htm">Sympathomimetics, Beta<sub>2</sub></a></td><td><p><span>increased risk of hypokalaemia when </span> <span>corticosteroids</span> <span>given with high doses of</span> <span>beta<sub>2</sub> sympathomimetics</span> <span>—see Hypokalaemia, <a title="CSM hypokalaemia (target-block)" href="PHP1734-selective-beta-2-agonists.htm#PHP1741">section 3.1.1.1</a></span>  </p></td><td></td></tr><tr><td><a href="bnf_int734-theophylline.htm">Theophylline</a></td><td><p><span>increased risk of hypokalaemia when </span> <span>corticosteroids</span> <span>given with</span> <span>theophylline</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int757-vaccines.htm">Vaccines</a></td><td class="cAI"><p><span>high doses of </span> <span>corticosteroids</span> <span>impair immune response to</span> <span>vaccines</span> <span>, avoid concomitant use with live <span>vaccines</span> (see under Active immunity, <a title="target-block: contra-indications" href="PHP8210-active-immunity.htm#PHP8219">section 14.1</a>)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> For a general warning on live vaccines and high doses of corticosteroids or other immunosuppressive drugs, see <a title="target-block: contra-indications" href="PHP8210-active-immunity.htm#PHP8219">section 14.1</a>; for advice on live vaccines and immunoglobulins, see under Normal Immunoglobulin, <a title="Normal immunoglobulin notes (target-block)" href="PHP8431-normal-immunoglobulin.htm#PHP8432">section 14.5.1</a></p></div></td></tr><tr><td><a href="bnf_int626-vecuronium.htm">Vecuronium</a></td><td><p><span></span> <span>corticosteroids</span> <span>possibly antagonise effects of</span> <span>vecuronium</span> <span></span>  </p></td><td></td></tr></tbody></table></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="bnf_int968-mometasone.htm">Previous: Mometasone</a> | <a class="top" href="bnf_int495-beclometasone.htm#">Top</a> | <a accesskey="]" href="bnf_int487-betamethasone.htm">Next: Betamethasone</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>